Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Supernus Pharmaceuticals, Inc.SUPN · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required |
| Reliability | 0.91 AUCfailure model, filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| Peer failure rate | 1.01% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $591M to $2.67B assetstotal assets $1.5B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | thin data · fortress balance sheetnot computable: distress |
| Inputs computable | 5 of 14 |
| Graded from | filings received through Mar 2, 2026221 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $42.152026-10-08; market equity $2.5B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 2, 2026; the document on sec.gov.
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 42.7 | |||||||
| Gross profitability | 44.4% | [1-2,5] | 32.2% | 27.2 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| a prior annual debt, equity, and cash observation is required | |||||||
| Accruals ratio | (6.1%) | [1,6-8] | (6.6%) | 58.3 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five consecutive annual gross margins are required | |||||||
| Solvency, sleeve percentile 45.7 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | 5.11 | [1,9-14] | (0.31) | 18.4 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 1.90x | [9-10] | 2.96x | 72.9 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 38.7 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four consecutive annual observations are required | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 11 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | not computable | 2.1% | |||||
| four consecutive annual observations are required | |||||||
| Net share issuance, one year | 3.2% | [15-16] | 2.5% | 38.7 | 634 | 2026-02-24 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (7.5%) | 8.0% | 42 | hotter than 42 of 100 peers |
| Distance from 52-week high | (26.1%) | (31.4%) | 58 | closer to its high than 58 of 100 peers |
| EBIT to enterprise value | (2.7%) | (1.5%) | 46 | pricier than 54 of 100 peers |
| Free cash flow yield | 1.9% | (1.0%) | 65 | pricier than 35 of 100 peers |
| Book value to price | 0.42 | 0.28 | 63 | pricier than 37 of 100 peers |
| Sales to price | 0.29 | 0.31 | 47 | pricier than 53 of 100 peers |
| Composite equity issuance, five years | 9.4% | 20.3% | 39 | more equity-funded than 39 of 100 peers |
| Relative strength against the sector, log excess return | (0.29) | (0.14) | 42 | ahead of 42 of 100 peers |
Inputs: market equity $2.4B; EBIT -$62.3M; free cash flow $46.0M; book equity $1.0B; sales $719.0M; debt $23.2M; cash $180.0M[17].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (2.8%) | ✗ fail[6,8] |
| Operating cash flow above zero | $47.3M | ✓ pass[7] |
| Return on assets improved | n/a[6,8,18] | |
| Operating cash flow exceeds net income | $85.9M | ✓ pass[6-7] |
| Long-term leverage fell | n/a[1,8] | |
| Current ratio improved | (44.1 pts) | ✗ fail[9-10,19-20] |
| No new shares issued | 3.2% | ✗ fail[15-16] |
| Gross margin improved | 1.4 pts | ✓ pass[2,5,21-22] |
| Asset turnover improved | n/a[2,8,21] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $180.0M[23] |
| Operating cash flow, four quarters | $19.9M[7,23-27] |
| Months of runway | not finite |
| trailing operating cash flow is nonnegative, so runway is not finite | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 67 |
| 10-Q received Aug 3, 2026 | |
| Median daily dollar volume | $26.5M |
| 63 sessions | |
| Days since newest grade input | 221 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $1.5B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $719.0M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $40.3M | 2012-12-31 | 2017-01-20 | 10-K/A | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebt | $23.2M | 2012-12-31 | 2013-03-15 | 10-K | filing · viewer · series |
| 5 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $74.6M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$38.5M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $47.3M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $1.4B | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 9 | current assets | us-gaap:AssetsCurrent | $644.2M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 10 | current liabilities | us-gaap:LiabilitiesCurrent | $338.2M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 11 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $517.9M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 12 | operating income | us-gaap:OperatingIncomeLoss | -$62.3M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 13 | book equity | us-gaap:StockholdersEquity | $1.1B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 14 | liabilities | us-gaap:Liabilities | $390.9M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 57,581,712 | 2026-02-24 | 2026-03-02 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 55,814,496 | 2025-02-18 | 2025-02-25 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 58,127,013 | 2026-07-28 | 2026-08-03 | 10-Q | filing · viewer · series |
| 18 | net income | us-gaap:NetIncomeLoss | $73.9M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 19 | current assets | us-gaap:AssetsCurrent | $686.1M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 20 | current liabilities | us-gaap:LiabilitiesCurrent | $292.4M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $661.8M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 22 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $77.9M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 23 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $180.0M | 2026-06-30 | 2026-08-03 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $61.7M | 2026-06-30 | 2026-08-03 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $66.5M | 2026-03-31 | 2026-05-05 | 10-Q | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $27.5M | 2025-09-30 | 2025-11-06 | 10-Q | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $89.1M | 2025-06-30 | 2026-08-03 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
